Hayashi, Toshiyuki
Fukui, Tomoyasu
Nakanishi, Noriko
Yamamoto, Saki
Tomoyasu, Masako
Osamura, Anna
Ohara, Makoto
Yamamoto, Takeshi
Ito, Yasuki
Hirano, Tsutomu
Clinical trials referenced in this document:
Documents that mention this clinical trial
Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin
https://doi.org/10.1186/s12933-016-0491-5
Funding for this research was provided by:
AstraZeneca K.K
Astellas Pharma Inc.
MSD K.K.
Ono Pharmceutical Co., Ltd.
Article History
Received: 3 October 2016
Accepted: 26 December 2016
First Online: 13 January 2017
Change Date: 13 November 2017
Change Type: Correction
Change Details: Following publication of the original article [1], the authors identified a number of errors. In Result (P.3), Table 1 (P.4), Table 5 (P.9) and Supplementary Table 1, the correct unit for adiponectin was μg/mL. In Table 1 (P.4), the correct value for the post treatment body weight in dapagliflozin was 76.2±14.8. In Table 6 (P.10), the correct value for the pre treatment sd LDL/LDL-C in decreased LDL-C group was 0.38±0.10.